![Vasily Fedorin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vasily Fedorin
Direttore operativo presso
4BIO Ventures Management Ltd.
Profilo
Vasily Fedorin is currently the Chief Operating Officer at 4BIO Ventures Management Ltd. He previously worked as a Marketing Manager at MS WESTFALIA GmbH from 2009 to 2010.
Dr. Fedorin holds a doctorate degree from Lomonosov Moscow State University Business School, which was conferred in 2008.
Posizioni attive di Vasily Fedorin
| Società | Posizione | Inizio |
|---|---|---|
4BIO Ventures Management Ltd.
 4BIO Ventures Management Ltd. Investment ManagersFinance 4bio Ventures invest in companies located in the United Kingdom. The firm targets the companies operating in the fields of gene therapy, cell theray, RNA based therapy, targeted therapies and microbiome. They provide financing for early stage capital requirements. | Direttore operativo | 01/03/2022 |
Precedenti posizioni note di Vasily Fedorin
| Società | Posizione | Fine |
|---|---|---|
MS WESTFALIA GmbH
 MS WESTFALIA GmbH Medical DistributorsDistribution Services Distributes medical equipment | Investitore di Private Equity | 01/02/2010 |
Formazione di Vasily Fedorin
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
8
Relazioni di 1° grado
3
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
MS WESTFALIA GmbH
MS WESTFALIA GmbH Medical DistributorsDistribution Services Distributes medical equipment | Distribution Services |
Lomonosov Moscow State University Business School
 Lomonosov Moscow State University Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4bio Ventures invest in companies located in the United Kingdom. The firm targets the companies operating in the fields of gene therapy, cell theray, RNA based therapy, targeted therapies and microbiome. They provide financing for early stage capital requirements. | Finance |
